Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis
調査の概要
詳細な説明
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis.
The main symptoms of patients with IPF are dyspnea on exertion and a persistent dry cough or mildly productive cough.
In many IPF patients, cough is often the first symptom, preceding dyspnea on exertion sometimes by years. It affects upwards of 70-85% of patients with IPF.
Chronic obstructive pulmonary disease (prevalence rate 4-18%) and asthma (prevalence rate 5.9-9.9%) are the airway disease whose main symptoms are also dyspnea and cough.
To date, the effect of airway disease has not been well studied in patients with idiopathic pulmonary fibrosis, and the prevalence is unknown in Korea.
Unlike idiopathic pulmonary fibrosis, airway disease is a treatable, modifiable disease, so treatment of these diseases may improve QOL in IPF patients.
Therefore, this study's purpose is A. Identify the prevalence of airway disease in IPF patients B. Identify differences in QOL and symptoms according to presence of airway disease C. Identify the symptomatic improvement after active treatment for the airway diseases
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Seoul、大韓民国
- 募集
- Seoul National University Hospital
-
コンタクト：
- Choi Sun Mi
- 電話番号：02-2072-4915
- メール：sunmich81@gmail.com
-
コンタクト：
- PARK HEEMOON
- メール：coramdeo33@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- IPF patients
Exclusion Criteria:
- Patients on systemic steroid
- Patients with acute exacerbation within the last 6 months
- PFT+BDR, MBPT contra-indication
- SpO2 < 90%
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of participants who have asthma combined with idiopathic pulmonary fibrosis
時間枠：Through study completion, an average of 2 year
|
Confirmation of asthma : pulmonary function test with bronchodilator response or Methacholine provocation test
|
Through study completion, an average of 2 year
|
|
Number of participants who have COPD combined with idiopathic pulmonary fibrosis
時間枠：Through study completion, an average of 2 year
|
Confirmation of COPD : pulmonary function test with bronchodilator response
|
Through study completion, an average of 2 year
|
|
Number of participants who have Eosinophilic bronchitis combined with idiopathic pulmonary fibrosis
時間枠：Through study completion, an average of 2 year
|
Confirmation of Eosinophilic bronchitis : pulmonary function test with bronchodilator response, induced sputum
|
Through study completion, an average of 2 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The difference of CAT scores between patients with airway disease and those without airway disease.
時間枠：baseline and after treating the airway disease for 6~8 weeks
|
Quality of life : COPD assessment test(CAT)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of SGRQ scores to assess quality of life between patients with airway disease and those without airway disease.
時間枠：baseline and after treating the airway disease for 6~8 weeks
|
Quality of life : St George's Respiratory Questionnaire(SGRQ)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease.
時間枠：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : mMRC
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease.
時間枠：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : 6 minute walking test(6MWT)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of EQ-5D-VAS scores to assess symptom severity between patients with airway disease and those without airway disease.
時間枠：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : EQ-5D-VAS
|
baseline and after treating the airway disease for 6~8 weeks
|
|
The difference of CQLQ scores to assess symptom severity between patients with airway disease and those without airway disease.
時間枠：baseline and after treating the airway disease for 6~8 weeks
|
Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ)
|
baseline and after treating the airway disease for 6~8 weeks
|
|
Checking the improvement of CAT score to assess the quality of life between patients with airway disease and those without airway disease
時間枠：After treating the airway disease for 6~8 weeks
|
Quality of life : COPD assessment test(CAT)
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of SGRQ score to assess the quality of life between patients with airway disease and those without airway disease
時間枠：After treating the airway disease for 6~8 weeks
|
Quality of life : St George's Respiratory Questionnaire(SGRQ)
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of mMRC scores to assess symptom severity between patients with airway disease and those without airway disease
時間枠：After treating the airway disease for 6~8 weeks
|
Symptom severity : mMRC
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of distance of 6MWT to assess symptom severity between patients with airway disease and those without airway disease
時間枠：After treating the airway disease for 6~8 weeks
|
Symptom severity : 6 minute walking test(6MWT)
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of EQ-5D-VAS score to assess symptom severity between patients with airway disease and those without airway disease
時間枠：After treating the airway disease for 6~8 weeks
|
Symptom severity : EQ-5D-VAS
|
After treating the airway disease for 6~8 weeks
|
|
Checking the improvement of CQLQ to assess symptom severity between patients with airway disease and those without airway disease
時間枠：After treating the airway disease for 6~8 weeks
|
Symptom severity : Cough Quality-of-Life Questionnaire(CQLQ)
|
After treating the airway disease for 6~8 weeks
|
協力者と研究者
捜査官
- 主任研究者：Choi Sun Mi、Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung institute, Seoul National University College of Medicine, Seoul, Korea
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。